Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Neuroleptic

or [[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]]

Use the filters below to narrow your results.

Amantadine (1) · Apomorphine (1) · Asenapine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Chlorpromazine (1) · Ciprofloxacin (1) · Droperidol (1) · Entacapone (1) · Fluphenazine (1) · Iloperidone (1) · Levodopa (1) · Levofloxacin (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Moxifloxacin (1) · Ofloxacin (1) · Opicapone (1) · Paliperidone (1) · Perphenazine (1) · Pimozide (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Thioridazine (1) · Thiothixene (1) · Tolcapone (1) · Trifluoperazine (1) · Trihexyphenidyl (1) · Ziprasidone (1)

None (1) · Akineton (1) · Apokyn (1) · Artane (1) · Avelox (oral/IV brand discontinued US); Vigamox, Moxeza (ophthalmic) (1) · Azilect (1) · Cipro, Cipro XR, Ciloxan (ophthalmic) (1) · Cogentin (1) · Comtan (1) · Dostinex (1) · Eldepryl (1) · Fanapt (1) · Floxin (oral, US brand discontinued); Ocuflox (ophthalmic); Floxin Otic (otic) (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Neupro (1) · Ongentys (1) · Orap (1) · Parlodel (1) · Prolixin (1) · Saphris (1) · Sinemet (1) · Stelazine (1) · Symmetrel (1) · Tasmar (1) · Thorazine (1) · Trilafon (1) · Xadago (1)

None (2) · Butyrophenone D2 antagonist (1) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Phenothiazine D2 antagonist (4) · Selective M1 muscarinic antagonist (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000D7A-QINU`"' Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities'"`UNIQ--ref-00000D7B-QINU`"'. (1) · '"`UNIQ--vote-000014BC-QINU`"' Topical ophthalmic and otic formulations remain widely used in ENT and ophthalmology. Subject to all fluoroquinolone-class restrictions (tendinitis/rupture, peripheral neuropathy, QT prolongation)'"`UNIQ--ref-000014BD-QINU`"'. (1)

None (31) · 400 mg PO/IV once daily (1) · 500-750 mg PO BID; 400 mg IV q8-12h (1) · 500-750 mg PO/IV once daily (1) · Oral 200-400 mg BID; ophthalmic 1-2 drops in affected eye(s) q2-4h initially, then taper; otic 5-10 drops in affected ear BID (1)

None (31) · 200, 300, 400 mg tablets (mostly generic now); 0.3% ophthalmic solution; 0.3% otic solution (1) · 250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) · 250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions (1) · 400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1)

None (31) · 400 mg/d (1) · 750 mg/d (1) · 800 mg/d (1) · ~1500 mg/d (oral); 1200 mg/d (IV) (1)

None (31) · IV (3) · ophthalmic (1) · Oral (4) · otic (2) · topical ophthalmic (3)

None (31) · Hours (4)

None (31) · 12 hours (1) · 24 hours (2) · 8-12 hours (1)

None (31) · 4 hours'"`UNIQ--ref-00000938-QINU`"' (1) · ~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) · ~6-8 hours'"`UNIQ--ref-00000CF5-QINU`"' (1) · ~9 hours'"`UNIQ--ref-000014C3-QINU`"' (1)

None (31) · ~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) · ~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' (1) · ~95% (oral)'"`UNIQ--ref-000014C4-QINU`"' (1) · ~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"' (1)

None (31) · '''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · '''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).[[[Pharmacopedia:Citation needed|citation needed]]] (2) · '''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (32) · [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-000014C5-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis'"`UNIQ--ref-00000CF7-QINU`"' (1)